On 2016 Nov 18, David Keller commented:

This study supports a controlled clinical trial of ibuprofen for treatment of Parkinson's disease

This study found that users of ibuprofen had a significant 38% reduction in their adjusted risk of Parkinson disease (PD) compared with nonusers of ibuprofen. Furthermore, a significant dose-response relationship was observed between the number of ibuprofen tablets taken per week and the reduction in PD risk. Further still, an accompanying meta-analysis found a significant 27% reduction in the risk of PD with ibuprofen use, but not with other NSAIDs.

The above three results [1] strongly support the authors' suggestion that "ibuprofen should be further investigated as a potential neuroprotective agent against PD". In particular, a randomized, placebo-controlled trial of ibuprofen in the setting of early PD seems justified, yet has not been reported in the years since the publication of this paper in 2011. Can anyone explain why?

Reference

1: Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology. 2011 Mar 8;76(10):863-9. doi:10.1212/WNL.0b013e31820f2d79. PubMed PMID: 21368281; PubMed Central PMCID:PMC3059148.

On 2016 Nov 18, David Keller commented:

This study supports a controlled clinical trial of ibuprofen for treatment of Parkinson's disease

This study found that users of ibuprofen had a significant 38% reduction in their adjusted risk of Parkinson disease (PD) compared with nonusers of ibuprofen. Furthermore, a significant dose-response relationship was observed between the number of ibuprofen tablets taken per week and the reduction in PD risk. Further still, an accompanying meta-analysis found a significant 27% reduction in the risk of PD with ibuprofen use, but not with other NSAIDs.

The above three results [1] strongly support the authors' suggestion that "ibuprofen should be further investigated as a potential neuroprotective agent against PD". In particular, a randomized, placebo-controlled trial of ibuprofen in the setting of early PD seems justified, yet has not been reported in the years since the publication of this paper in 2011. Can anyone explain why?

Reference

1: Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology. 2011 Mar 8;76(10):863-9. doi:10.1212/WNL.0b013e31820f2d79. PubMed PMID: 21368281; PubMed Central PMCID:PMC3059148.